Journal
NEUROSCIENCE LETTERS
Volume 690, Issue -, Pages 178-180Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2018.10.040
Keywords
Neuroprotection; Dopaminergic MN9D cells; miRNA upregulation
Categories
Funding
- Texas Tech University Health Sciences Center El Paso Graduate School of Biomedical Sciences
- Fogarty International Center - U.S./Costa Rica Neuropsychiatric Genetics Research Training Program [NCOD-5D43TW008333]
- Hoy Family Research
- Perez Family Research
- Lizanell and Colbert Coldwell Foundation
- Ms. Anna Mae Doyle Gift Funds
- Multiple System Atrophy (MSA) Coalition
- El Paso Community Foundation
Ask authors/readers for more resources
In searching for Parkinson's disease (PD) pharmacotherapies we began studying FTY720, a food and drug administration (FDA) approved drug. We also created derivatives, FTY720-C2 and FTY720-Mitoxy, and began assessing them. Here we treated dopaminergic MN9D cells with FTY720s then measured microRNA (miRNA) levels by PCR arrays. We discovered that all three FTY720s increased miR376b-3p, while FTY720-C2 also increased miR-128-3p, miR-146b-5p, miR-7a-5p, and miR-9-5p, and FTY720-Mitoxy also increased miR-30d-5p. Investigations revealed that some miRNAs downregulate alpha-synuclein, while others reduce apoptosis, suggesting that FTY720s may act to reduce synucleinopathy and dopaminergic neuron loss in PD and related disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available